Plasma FFAs reduction by acipimox (a potent lipolysis inhibitor) improves insulin sensitivity and skeletal muscle mitochondrial adenosine triphosphate (ATP) synthesis in both insulin resistant obese with normal glucose tolerance and in patients with T2D, suggesting that the mitochondrial defect may be reversible (21,22). This evidence concerns the gene INS and type 2 diabetes mellitus.